Skip to main content

Advertisement

Table 2 Summary of dose reductions and delays

From: Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Characteristic Number %
Dose reductions and delays per patient
 Number of patients 39  
  Dose delays 24 61.5
  Dose reductions 11 28.2
Dose reductions and delays per cycle
 Number of cycles 215  
  Dose delays 47 21.9
  Dose reductions
   5-Fluorouracil 33 15.3
   Oxaliplatin 39 18.1
   Irinotecan 46 21.4